Metabolic Profiling of Candida auris, a Newly-Emerging Multi-Drug Resistant Candida Species, by GC-MS
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Candida auris, a newly-emerging Candida species, is a serious global health threat due to its multi-drug resistant pattern, difficulty to diagnose, and the high mortality associated with its invasive and bloodstream infections. Unlike C. albicans, and C. dubliniensis which can form true hyphae, C. auris grows as yeast or pseudohyphae and is capable of developing biofilms. The reasons for the inability of C. auris to form true hyphae are currently unknown. Metabolites secreted by microorganisms, including Candida, are known as important factors in controlling morphogenesis and pathogenesis. Metabolic profiling of C. auris and C. albicans cultures was performed using gas chromatography–mass spectrometry (GC–MS). Compared to C. albicans, C. auris secreted several hyphae-inhibiting metabolites, including phenylethyl, benzyl and isoamyl alcohols. Furthermore, a biofilm-forming metabolite—tyrosol—was identified. On the other hand, several other biomarkers identified from C. auris but not from C. albicans cultures may be produced by the organism to overcome the host immune system or control fungal adaptations, and hence ease its invasion and infections. The results from this study are considered as the first identification of C. auris metabolic activities as a step forward to understand its virulence mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
The distinct morphogenic states of Candida albicans
Sudbery, P., Gow, N., & Berman, J. (2004) · Trends in Microbiology · doi:10.1016/j.tim.2004.05.008 · Cited by 876 · cited 1×
“albicans responds to environmental changes by developing different polymorphic forms including yeast, pseudo-hyphae and true hyphae [20,21].”
BackgroundChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Al-Lahham, S. H., Peppelenbosch, M. P., Roelofsen, H., Vonk, R. J., & Venema, K. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.07.007 · Cited by 614
Multidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373 · cited 2×
“It is reported that the aforementioned alcohols including phenylethyl, benzyl and isoamyl alcohols are hyphae-inhibiting metabolites [3,12,23], while tyrosol is a filamentation and biofilm-forming metabolite [16].”
BackgroundCandida auris candidaemia in Indian ICUs: analysis of risk factors
Rudramurthy, S. M., Chakrabarti, A., Paul, R. A., Sood, P., Kaur, H., Capoor, M. R., Kindo, A. J., Marak, R. S. K., Arora, A., Sardana, R., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx034 · Cited by 357 · cited 1×
“However, the major manifestation of the infection includes invasive and bloodstream infections [9].”
BackgroundNiche-specific regulation of central metabolic pathways in a fungal pathogen
Barelle, C. J., Priest, C. L., MacCallum, D. M., Gow, N. A. R., Odds, F. C., & Brown, A. J. P. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00676.x · Cited by 336
Arendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270 · cited 1×
“auris as an emerging serious global health threat mainly because of its multidrug-resistant pattern associated with high mortality rate that can reach 60% [2,3], difficulty to diagnose [4] and recent outbreaks in healthcare settings owing to the yeast persistence as a colonizer on abiotic surfaces [5].”
BackgroundPotential Use of Phenolic Acids as Anti-Candida Agents: A Review
Teodoro, G. R., Ellepola, K., Seneviratne, C. J., & Koga-Ito, C. Y. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01420 · Cited by 204 · cited 1×
“auris produced autotoxic metabolites including tryptophol [35], propanoic [36], benzoic [37], octanoic acid (caprylic acid) [38], benzeneacetic acid (phenyl acetic acid) [37], glyceric [39], kojic [40,41], dodecanoic (lauric) [42,43] acids and pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl) [44] that ca…”
Background
Cited by
Fayed, B., Jayakumar, M. N., & Soliman, S. S. M. (2021) · Medical Mycology · doi:10.1093/mmy/myab059 · Cited by 41
Self-citationNative human and mouse skin infection models to study Candida auris-host interactions
Seiser, S., Arzani, H., Ayub, T., Phan-Canh, T., Staud, C., Worda, C., Kuchler, K., & Elbe-Bürger, A. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2023.105234 · Cited by 29
Antifungal Activity of Plant Secondary Metabolites on Candida albicans: An Updated Review
Khan, A., Moni, S. S., Ali, M., Mohan, S., Jan, H., Rasool, S., Kamal, M. A., Alshahrani, S., Halawi, M., & Alhazmi, H. A. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467215666220304143332 · Cited by 17
Metadata
- Authors
- Semreen, M. H., Soliman, S. S. M., Saeed, B. Q., Alqarihi, A., Uppuluri, P., & Ibrahim, A. S.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-01-22
- Volume
- 24
- Issue
- 3
- Pages
- 399
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2914003150
- Cited by
- 47
- References
- 13
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.